Total amount: € 0,00
D’amico D., De Giacomo P., Ferri R., Valenti G.
Unità Operativa Complessa di Dermatologia, Azienda Ospedaliera “Pugliese-Ciaccio”, Catanzaro
Aim. The aim of this study was to present an often underestimated pathology, nail psoriasis, a clinically significant condition that diminishes the patient’s quality of life.
Methods. From October 2005 to June 2006 12 patients were enrolled into the study. Eligible patients were those who within the PsoCare project had begun systemic etanercept therapy (Enbrel, Wyeth), 25 mg twice weekly for psoriasis vulgaris or psoriatic arthropathy and who presented with a Nail Psoriasis Severity Index (NAPSI. ≥15).
Results. During the 104 weeks of the study, etanercept was found to be efficacious in resolving psoriasis, as indicated in the technical data sheet; a reduction in the PASI to 75 was noted by week 32 into the study.
Conclusion. The drug demonstrated optimal efficacy in clearing nail manifestations.
language: English, Italian